Description
Non-Fucosylated Anti-Human CD22 (Moxetumomab pasudodox) is a glycosylation-modified therapeutic biobetter antibody.
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD22 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD22
Full Name
CD22 Molecule
Background
CD22 (CD22 Molecule) is a Protein Coding gene.
Diseases associated with CD22 include Refractory Hematologic Cancer and Refractory Hairy Cell Leukemia.
Among its related pathways are Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers and Innate Immune System.
Gene Ontology (GO) annotations related to this gene include carbohydrate binding.
An important paralog of this gene is SIGLEC1.
Alternative Names
Epratuzumab; LymphoCide; 205923-57-5; AMG 412; hLL2; DB04958CD22; CD22 molecule; CD22 antigen; B-cell receptor CD22; sialic acid binding Ig like lectin 2; SIGLEC 2; SIGLEC2; BL-CAM; T-cell surface antigen Leu-14; B-lymphocyte cell adhesion molecule;
Gene ID
933
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG2/4
Antibody Clone
Moxetumomab pasudodox
Description
This clone was generated using a stable CHO cell line with the FUT8 knockout gene. It was 100% non-fucosylated. In an in vitro cell-based ADCC assay, the afucosylated antibody clone showed significantly higher ADCC activity compared to its wild type version. The binding affinity of the non-fucosylated Fc variant antibody to Fc receptor is much higher than than the same antibody with fucosylated Fc. Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved.
